These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 36400804)
21. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023 [TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A; J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777 [TBL] [Abstract][Full Text] [Related]
23. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV; Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229 [TBL] [Abstract][Full Text] [Related]
24. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676 [TBL] [Abstract][Full Text] [Related]
25. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825 [TBL] [Abstract][Full Text] [Related]
26. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status. Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J Front Immunol; 2024; 15():1392477. PubMed ID: 38774878 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933 [TBL] [Abstract][Full Text] [Related]
28. Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants. Jäger M; Diem G; Sahanic S; Fux V; Griesmacher A; Lass-Flörl C; Wilflingseder D; Tancevski I; Posch W J Infect Dis; 2023 Jul; 228(2):160-168. PubMed ID: 36869832 [TBL] [Abstract][Full Text] [Related]
36. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I Front Immunol; 2023; 14():1099246. PubMed ID: 36756112 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H Front Immunol; 2023; 14():1170759. PubMed ID: 37180152 [TBL] [Abstract][Full Text] [Related]
38. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152 [TBL] [Abstract][Full Text] [Related]
39. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746 [TBL] [Abstract][Full Text] [Related]
40. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]